Overview
- More than 500 suspected adverse reaction reports tied to GLP‑1 medicines were filed from Northern Ireland in 2024–25, with 242 classified as serious.
- Two fatalities were reported to the MHRA as suspected reactions, one associated with Mounjaro (tirzepatide) and the other with an unspecified semaglutide product.
- Six suspected cases of acute pancreatitis were recorded over the two years, including three linked by reporters to Mounjaro and one to Ozempic.
- Most submissions came from healthcare professionals (419), with 92 from patients, parents or carers, and one serious report involved a child under 10.
- The MHRA says it is continuing active safety surveillance and urges ongoing Yellow Card reporting, stating the benefits of licensed GLP‑1 use currently outweigh potential risks.